Patient satisfaction of radiofrequency ablation for symptomatic benign solid thyroid nodules: our experience for 2-year follow up

Table 2 Changes in VRR of TNs after RFA treatment at each follow-up

	Small ≤ 5 ml (n = 38)		Medium 5.1–13 ml (n = 86)		Intermediate 13.1–30 ml (n = 43)		Large >30 ml (n = 27)
	Mean ± SD	Range	Mean ± SD	Range	Mean ± SD	Range	Mean ± SD	Range
1 month	67.2 ± 10.7	37.2–86.3	61.2 ± 11.1	24.5–80.3	53.1 ± 15.7	15.6–79.3	37.1 ± 16.2	12.3–54.3
3 months	79.5 ± 9.6^a	43.3–100	73.3 ± 10.8^a	35.2–91.2	65.9 ± 13.1^a	28.1–84.5	49.3 ± 15.6^a	27.3–65.3
6 months	87.6 ± 8.2^a	54.7–100	79.4 ± 9.4^a	46.7–100	71.4 ± 12.6^a	41.5–89.3	57.8 ± 14.9^a	38.2–74.7
12 months	93.3 ± 5.9^a	69.4–100	83.1 ± 7.2^a	63.2–100	78.6 ± 11.5^a	56.3–90.6	65.6 ± 13.4^a	47.2–81.3
18 months	95.5 ± 3.7^a	76.2–100	87.8 ± 5.3^a	73.6–100	81.4 ± 9.3^a	59.7–91.7	70.8 ± 11.1^a	57.1–86.4
24 months	98.7 ± 1.3^a	85.6–100	92.4 ± 3.2^a	78.2–100	87.5 ± 4.6^a	61.8–93.6	72.3 ± 10.3^a	60.7–89.7

VRR volume reduction ratio, TNs thyroid nodules, RFA radiofrequency ablation,
^a < .001

ISSN: 1471-2407